Eyebright Medical(SH:688050) Xin Lang Cai Jing·2025-09-23 06:06Group 1 - Aibo Medical experienced a decline of 5.02% on September 23, with a stock price of 72.28 yuan per share, a trading volume of 239 million yuan, a turnover rate of 1.71%, and a total market capitalization of 13.979 billion yuan [1] - Aibo Medical, officially known as Aibo Nord (Beijing) Medical Technology Co., Ltd., was established on April 21, 2010, and went public on July 29, 2020. The company specializes in the research, development, production, sales, and related services of ophthalmic medical devices [1] - The main revenue composition of Aibo Medical includes: artificial lenses (43.86%), contact lenses (30.06%), orthokeratology lenses (15.14%), other myopia control products (6.01%), other surgical products (2.37%), other vision care products (1.62%), and other income (0.95%) [1] Group 2 - Southern Fund has one fund heavily invested in Aibo Medical, specifically the Southern Pharmaceutical Health Flexible Allocation Mixed A (000452), which held 2.1312 million shares in the second quarter, unchanged from the previous period, accounting for 6.07% of the fund's net value, making it the second-largest holding [2] - The estimated floating loss for the fund on the current day is approximately 8.1412 million yuan [2] - The Southern Pharmaceutical Health Flexible Allocation Mixed A (000452) was established on January 23, 2014, with a latest scale of 2.405 billion yuan. Year-to-date returns are 50.93%, ranking 1016 out of 8172 in its category; the one-year return is 57.98%, ranking 2533 out of 7995; and since inception, the return is 242.22% [2]